evaluate the pharmaceuticals company wegovy on glp-1 drugs for diabetes US FDA accepts Novo Nordisk's application oral for weight loss Novo Nordisk, Hims & Hers
Description
3 Minimizing Side Effects The good news about the side effects is that many of these meds come in doses that can be slowly increased over time
Cornier MA
This exclusion is significant considering that patients with obesity have a higher risk of developing depression 24
Development of GLP-1 receptor agonists The most important strategy to develop compounds with extended in vivo half-life of GLP-1 was by making DPP-4 resistant GLP-1 receptor agonists
That is exactly the population in which a GLP-1 add-on or substitution becomes relevant
